The method described here allows for the simultaneous analysis of 47 pesticides and five mycotoxins in cannabis in one simple QuEChERS procedure. This simple method is designed for implementation in start-up laboratories and in established laboratories that wish to streamline their sample preparation process, decrease solvent usage, and obtain accurate and fast results.
An investigation of C18 and phenyl-hexyl column chemistries for definitive identification of 13 synthetic cannabinoid metabolites in patient samples.
The Benefits of ICP-MS for the Determination of Toxic and Nutritional Elements in the Cannabis Family of Flowering Plants
The wide dynamic range of ICP-MS allows it to be used for the simultaneous determination of parts-per-billion levels of heavy metals including lead, arsenic, cadmium, and mercury, together with high parts-per-million levels of nutritional elements, such as phosphorus, calcium, potassium, and magnesium.
Rapid Determination of 24 Synthetic and Natural Cannabinoids for LC–MS-MS Screening in Natural Products and Drug Inspection Applications
Other techniques for monitoring cannabinoids, such as GC–MS and LC–MS, are limited to screening known species and are therefore always one step behind the designer drug market—where new, previously unknown variations of analogs of cannabinoids are constantly being synthesized. The method presented here addresses this problem by providing accurate masses for all detected species, thus allowing postanalysis identification of initially untargeted compounds.
An interview with Sue Sisley
Medical use of marijuana for a broad range of conditions is expanding rapidly in the US, as legalization gathers pace and investors flock to a booming market.
Efficient synthesis of complex cannabinoids is possible while avoiding marijuana cultivation.
On Feb. 7, 2017 GW Pharmaceuticals announced the results from a small Phase II study with tetrahydrocannabinol (THC) and cannabidiol (CBD) in 21 patients with recurrent glioblastoma multiforme (GBM).
AXIM Biotechnologies, a Netherlands-based biotechnology company, announced that it would be entering clinical trials with its patent-pending cannabigerol (CBG) topical ointment formulation AX-1602, the company said in a May 16, 2016 press
GW Pharmaceuticals, a London-based biopharmaceutical company focused on the development and commercialization of therapeutics derived from its cannabinoid product platform, announced on March 14, 2016 that it had successfully completed a